Expertise in
14
conditions

Dr. Mary Rinella

Hepatology
University Of Chicago
5841 S Maryland Ave, 
Chicago, IL 
28 Years of Experience
Expertise in
14
conditions
University Of Chicago
5841 S Maryland Ave, 
Chicago, IL 

Overview

Mary Rinella is a Hepatologist in Chicago, Illinois. Dr. Rinella has been practicing medicine for over 28 years is highly rated in 14 conditions, according to our data. Her top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, Cirrhosis, Liver Transplant, and Endoscopy.

Her clinical research consists of co-authoring 176 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hepatology

Licenses

Internal Medicine in IL

Hospital Affiliations

Northwestern Memorial Hospital
The University Of Chicago Medical Center
Adventist Hinsdale Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 13 Less Insurance Carriers -

Locations

UNIVERSITY OF CHICAGO
5841 S Maryland Ave, Chicago, IL 60637
Other Locations
UNIVERSITY OF CHICAGO
355 E Grand Ave, Chicago, IL 60611

Additional Areas of Focus

Dr. Rinella has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Enrollment Status: Completed
Publish Date: December 20, 2022
Intervention Type: Device
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 07, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients
A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients
Enrollment Status: Completed
Publish Date: May 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

176 Total Publications

MASLD as a complication of obesity must include liver risk stratification.
MASLD as a complication of obesity must include liver risk stratification.
Journal: Nature medicine
Published: January 07, 2026
Similar Doctors
Expertise in
20
conditions
Dr. Nancy Reau
Hepatology
Expertise in
20
conditions
Dr. Nancy Reau
Hepatology

Rush University Medical Group

1890 Silver Cross Blvd, Suite 215, 
New Lenox, IL 
 (26.0 miles away)
815-602-8251
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nancy Reau is a Hepatologist in New Lenox, Illinois. Dr. Reau is highly rated in 20 conditions, according to our data. Her top areas of expertise are Hepatitis C, Hepatitis, Autoimmune Hepatitis, Non-Alcoholic Fatty Liver Disease, and Liver Transplant.

Andres Duarte
Expertise in
17
conditions
Dr. Andres Duarte
Hepatology
Expertise in
17
conditions
Dr. Andres Duarte
Hepatology
259 E Erie St Ste 1600, Lavin Family Pavilion, 
Chicago, IL 
 (7.4 miles away)
312-695-4837
Experience:
25+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andres Duarte is a Hepatologist in Chicago, Illinois. Dr. Duarte has been practicing medicine for over 25 years is highly rated in 17 conditions, according to our data. His top areas of expertise are Liver Failure, Hepatitis, Cirrhosis, Liver Transplant, and Endoscopy.

Steven Flamm
Expertise in
23
conditions
Dr. Steven Flamm
Hepatology
Expertise in
23
conditions
Dr. Steven Flamm
Hepatology

Northwestern Medicine Liver Transplant Care-Aurora

2635 Church Rd, 
Aurora, IL 
 (35.1 miles away)
312-695-4837
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steven Flamm is a Hepatologist in Aurora, Illinois. Dr. Flamm is highly rated in 23 conditions, according to our data. His top areas of expertise are Hepatitis C, Hepatitis, Cirrhosis, Liver Transplant, and Endoscopy.

Frequently Asked Questions about Dr. Mary Rinella

How do I make an appointment with Dr. Mary Rinella?

You can book an appointment with Dr. Mary Rinella by calling their office at 888-824-0200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mary Rinella a top-rated expert for Nonalcoholic Steatohepatitis (NASH)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mary Rinella is classified as an Elite expert for Nonalcoholic Steatohepatitis (NASH), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mary Rinella specialize in?

While Dr. Mary Rinella is a Hepatology, they have specific expertise in Nonalcoholic Steatohepatitis (NASH), Non-Alcoholic Fatty Liver Disease, and Cirrhosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hepatology.

Does Dr. Mary Rinella participate in research or clinical trials?

Yes. Dr. Mary Rinella has published 176 articles and abstracts on conditions like Nonalcoholic Steatohepatitis (NASH). You can view a list of Dr. Mary Rinella's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mary Rinella accept my insurance?

Dr. Mary Rinella accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 888-824-0200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rinella's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile